The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i
The model's full reasoning — Q4 2022 call → NOWe need to determine if there is a specific negative outcome that investors/analysts/market are worried about, and if management pushes back with current, already-observed evidence. Looking at the transcript, there are a few potential worries. One is about the impact of faricimab (a competitor) and the temporary unavailability of co-pay funds, which affected Q4 growth. Management acknowledges this and says it was temporary, and that they expect growth to resume. But is that a specific fear? The analysts ask about it, and management explains the impact. However, management does not push back with evidence that the feared outcome (e.g., permanent loss of market share) is not materializing. They say it was temporary and that they expect to see growth going forward, but that's more of a forecast. Another worry might be about the need for additional capital, but management says they raised money to strengthen balance sheet and look for acquisitions. That's not a fear. Another worry: the NEW DAY study enrollment, but that's not a negative outcome. The question asks: is there a specific negative outcome that investors are worried about, and does management push back with current evidence? The faricimab competition and co-pay issue is a specific worry, but management's response is that it was temporary and they expect growth. They don't cite current evidence that the feared outcome (e.g., losing market share permanently) is not happening. They say "we think we will be able to see that going forward" - that's a projection. Also, the analyst asks about growth for 2023, and management says they model conservatively 10% growth and hope to be positively surprised. That's not a pushback with evidence. There is also the worry about the impact of currency fluctuations, but that's not a specific negative outcome that investors are worried about; it's just a fact. The question requires both halves: a named, company-specific fear that is live, and management answers with observed behavior. Here, the fear is about the impact of faricimab and co-pay shortfall on demand. Management acknowledges it and says it was temporary, but they don't provide evidence that demand has recovered or that the feared outcome (e.g., sustained decline) is not happening. They say "we think we will be able to see that going forward" - that's a forecast.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AVTR | Avantor, Inc. | Q2 2024 | 2024-07-26 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| TYGO | Tigo Energy, Inc. | Q4 2023 | 2024-02-14 | F |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| BBVA | Banco Bilbao Vizcaya Argentaria, S.A. | Q4 2023 | 2024-01-30 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| GMED | Globus Medical, Inc. | Q3 2023 | 2023-11-07 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| LNTH | Lantheus Holdings, Inc. | Q2 2023 | 2023-08-03 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| REYN | Reynolds Consumer Products Inc. | Q1 2023 | 2023-05-10 | C |
| DOCN | DigitalOcean Holdings, Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| AKR | Acadia Realty Trust | Q4 2022 | 2023-05-06 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| EPR | EPR Properties | Q1 2023 | 2023-04-27 | C+ |
| MEDP | Medpace Holdings, Inc. | Q1 2023 | 2023-04-25 | B+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| POOL | Pool Corporation | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| A | Agilent Technologies, Inc. | Q4 2022 | 2022-11-21 | B+ |
| PCTY | Paylocity Holding Corporation | Q1 2023 | 2022-11-05 | A |
| TT | Trane Technologies plc | Q3 2022 | 2022-11-02 | A |
| APOG | Apogee Enterprises, Inc. | Q2 2023 | 2022-09-20 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| ZBRA | Zebra Technologies Corporation | Q2 2022 | 2022-08-02 | C+ |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| DCGO | DocGo Inc. | Q1 2022 | 2022-05-14 | C |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| EGHT | 8x8, Inc. | Q4 2022 | 2022-05-10 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| BSX | Boston Scientific Corporation | Q1 2022 | 2022-04-27 | B |
| CCK | Crown Holdings, Inc. | Q1 2022 | 2022-04-26 | C+ |
| FR | First Industrial Realty Trust, Inc. | Q1 2022 | 2022-04-21 | A |
| SDIG | Stronghold Digital Mining, Inc. | Q3 2021 | 2021-11-30 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| HSY | The Hershey Company | Q3 2021 | 2021-10-28 | C |
| PEP | PepsiCo, Inc. | Q3 2021 | 2021-10-05 | B |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| PTVE | Pactiv Evergreen Inc. | Q2 2021 | 2021-08-08 | C+ |
| SPG | Simon Property Group, Inc. | Q2 2021 | 2021-08-02 | B |
| GLW | Corning Incorporated | Q2 2021 | 2021-07-27 | B+ |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| VLRS | Controladora Vuela Compañía de Aviación, | Q2 2021 | 2021-07-16 | B+ |
| MAR | Marriott International, Inc. | Q2 2018 | 2018-08-07 | B |
| VALE | Vale S.A. | Q2 2018 | 2018-07-26 | B |
| FICO | Fair Isaac Corporation | Q3 2018 | 2018-07-26 | C+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| TRUE | TrueCar, Inc. | Q1 2018 | 2018-05-08 | C |
| TGNA | TEGNA Inc. | Q1 2018 | 2018-05-08 | B+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| MIDD | The Middleby Corporation | Q4 2017 | 2018-02-28 | C |
| SBUX | Starbucks Corporation | Q1 2018 | 2018-01-26 | C |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| GURE | Gulf Resources, Inc. | Q3 2017 | 2017-11-14 | F |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCRX | BioCryst Pharmaceuticals, Inc. | Q1 2017 | 2017-05-07 | B |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| CGNT | Cognyte Software Ltd. | Q4 2016 | 2017-03-09 | D |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| LPSN | LivePerson, Inc. | Q1 2016 | 2016-05-04 | B |
| UVE | Universal Insurance Holdings, Inc. | Q1 2016 | 2016-05-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| VRTS | Virtus Investment Partners, Inc. | Q1 2016 | 2016-04-29 | D |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.